Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

BACKGROUND: There currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in whom two prior lines of therapy have failed. The randomised, phase III JAVELIN Gastric 300 trial compared avelumab versus physi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bang, Y -J, Ruiz, E Yañez, Van Cutsem, E, Lee, K -W, Wyrwicz, L, Schenker, M, Alsina, M, Ryu, M -H, Chung, H -C, Evesque, L, Al-Batran, S -E, Park, S H, Lichinitser, M, Boku, N, Moehler, M H, Hong, J, Xiong, H, Hallwachs, R, Conti, I, Taieb, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225815/
https://www.ncbi.nlm.nih.gov/pubmed/30052729
http://dx.doi.org/10.1093/annonc/mdy264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225815/
https://www.ncbi.nlm.nih.gov/pubmed/30052729
http://dx.doi.org/10.1093/annonc/mdy264

Ejemplares similares